Where does LFWD stock trade?

Lifeward Ltd. (LFWD) is listed on NASDAQ.

What sector and industry is LFWD in?

Lifeward Ltd. operates in the Health Care sector, Industrial Specialties industry.

When did Lifeward Ltd. go public?

Lifeward Ltd. (LFWD) completed its IPO in 2014.

What are analysts saying about LFWD?

Lifeward Ltd. has had 1 recent analyst action on file. The most recent action was from Laidlaw: Buy with a $1000.00 price target on 2025-02-10. Recent price targets cluster around $1000.00.

What companies are similar to LFWD?

Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare LFWD side-by-side with any of them on Quantisnow.

How can I track LFWD on Quantisnow?

Quantisnow aggregates Lifeward Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LFWD to receive live email and push alerts on every new disclosure.

LFWD

NASDAQ

Lifeward Ltd.

SectorHealth CareIndustryIndustrial SpecialtiesIPO2014

$7.02-0.87 (-10.97%)

News25/Ratings1

Price$7.02-0.76 (-9.71%)

2026-07-152026-10-15

News · 26 weeks50-71%

2026-04-192026-10-11

Mix2890d

SEC Filings12(43%)
Insider7(25%)
Other5(18%)
Leadership3(11%)
Earnings1(4%)

Latest news

25 items

2dPR
Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study
Study shows ReWalk can be used for years and provides measurable walking performance for people with chronic paraplegia ReWalk was used for a median of 33 months, with no reported falls or exoskeleton-related fractures during the observation period; participants maintained 3,000+ steps per month, demonstrating sustained real-world utilization Participants reported high satisfaction including improvements in quality of life, mental health, bowel and bladder management, as well as less pain Long-term real-world evidence adds to the growing body of data supporting broader access, reimbursement and adoption of ReWalk HUDSON, Mass. and YOKNEAM ILLIT, Israel and BERLIN, Oct. 14, 2026 (GLOBE
8dSEC
SEC Form 8-K filed by Lifeward Ltd.
8-K - Lifeward Ltd. (0001607962) (Filer)
15dSEC
Lifeward Ltd. filed SEC Form 8-K: Leadership Update
8-K - Lifeward Ltd. (0001607962) (Filer)
21dSEC
SEC Form DEF 14A filed by Lifeward Ltd.
DEF 14A - Lifeward Ltd. (0001607962) (Filer)
31dSEC
SEC Form PRE 14A filed by Lifeward Ltd.
PRE 14A - Lifeward Ltd. (0001607962) (Filer)
31dSEC
Lifeward Ltd. filed SEC Form 8-K: Shareholder Director Nominations
8-K - Lifeward Ltd. (0001607962) (Filer)
31dPR
Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use ReWalk users with chronic spinal cord injury were able to perform everyday kitchen and grooming activities while standing with a personal exoskeleton Publication adds to clinical evidence supporting ReWalk as sales and national distribution access continue to expand HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the p
36dINSIDER
Director Zamir Haggai was granted 6,711 units of Ordinary Shares (SEC Form 4)
4 - Lifeward Ltd. (0001607962) (Issuer)
36dINSIDER
SEC Form 3 filed by new insider Zamir Haggai
3 - Lifeward Ltd. (0001607962) (Issuer)
38dSEC
Lifeward Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Lifeward Ltd. (0001607962) (Filer)
38dPR
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an updated investor presentation is available on the Company's investor relations website. The presentation provides an overview of Lifeward's strategy to scale its established rehabilitation platform, leverage its reimbursement infrastructure, and expand its capital-efficient distribution network. It also highlights the Company's recent commercial performance, product development pipeline and strategic
45dINSIDER
SEC Form 3 filed by new insider Hexter Joshua
3 - Lifeward Ltd. (0001607962) (Issuer)
46dSEC
Lifeward Ltd. filed SEC Form 8-K: Leadership Update
8-K - Lifeward Ltd. (0001607962) (Filer)
46dPR
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of Josh Hexter as Interim Chief Executive Officer effective September 1, 2026 and Rami Aviram as Chief Financial Officer effective November 1, 2026. Hexter succeeds Mark Grant, who has chosen to leave Lifeward to pursue other opportunities after leading the development and implementation of the Company’s current commercial strategy. Grant will serve as a consultant with the Company through Sep
49dINSIDER
Director Greenwald Yonason was granted 6,711 units of Ordinary Shares (SEC Form 4)
4 - Lifeward Ltd. (0001607962) (Issuer)
49dINSIDER
SEC Form 3 filed by new insider Greenwald Yonason
3 - Lifeward Ltd. (0001607962) (Issuer)
53dINSIDER
Director Gabay Avraham was granted 13,643 units of Ordinary Shares (SEC Form 4)
4 - Lifeward Ltd. (0001607962) (Issuer)
53dINSIDER
SEC Form 3 filed by new insider Gabay Avraham
3 - Lifeward Ltd. (0001607962) (Issuer)
57dSEC
Lifeward Ltd. filed SEC Form 8-K: Leadership Update
8-K - Lifeward Ltd. (0001607962) (Filer)
60dPR
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
WALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension," "Nano," or the "Company") today announced the appointment of Nadav Kidron to its Board of Directors (the "Board"). As part of the Board’s ongoing strategic review, led by Chairman Phillip Borenstein, the Board intends to establish a Strategy and Capital Allocation Committee to support the Board’s evaluation of capital allocation alternatives, potential returns of excess capital to shareholders, monetization of non-core assets, strategic opportunities and other initiatives intended to maximize long-term shareholder value. Mr. Kidron will chair this committee and work with the Chairman, hi
63dSEC
SEC Form 10-Q filed by Lifeward Ltd.
10-Q - Lifeward Ltd. (0001607962) (Filer)
63dSEC
Lifeward Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
8-K - Lifeward Ltd. (0001607962) (Filer)
63dPR
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support continued commercial execution HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today reported financial results for the second quarter ended June 30, 2026. Corporate & Financial Highlights Revenue increased 16% to $6.6 million in the second quarter of 2026 compared to the second quarter of
66dSEC
SEC Form EFFECT filed by Lifeward Ltd.
EFFECT - Lifeward Ltd. (0001607962) (Filer)
70dPR
Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its second quarter 2026 financial results on Friday, August 14, 2026. A press release will be issued and quarterly report will be filed with the SEC prior to 9:30 a.m. ET. The Company will not conduct a conference call. About Lifeward Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfoli

LFWD FAQ

6 questions

Where does LFWD stock trade?
Lifeward Ltd. (LFWD) is listed on NASDAQ.
What sector and industry is LFWD in?
Lifeward Ltd. operates in the Health Care sector, Industrial Specialties industry.
When did Lifeward Ltd. go public?
Lifeward Ltd. (LFWD) completed its IPO in 2014.
What are analysts saying about LFWD?
Lifeward Ltd. has had 1 recent analyst action on file. The most recent action was from Laidlaw: Buy with a $1000.00 price target on 2025-02-10. Recent price targets cluster around $1000.00.
What companies are similar to LFWD?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare LFWD side-by-side with any of them on Quantisnow.
How can I track LFWD on Quantisnow?
Quantisnow aggregates Lifeward Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LFWD to receive live email and push alerts on every new disclosure.